Bacteriophage T4 as a nanoparticle platform to display and deliver pathogen antigens: Construction of an effective anthrax vaccine

Methods in Molecular Biology

Volumn 1581, Issue , 2017, Pages 255-267

  Tao, Pan ^a   Li, Qin ^a   Shivachandra, Sathish B ^a   Rao, Venigalla B ^a  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

Anthrax vaccine; Bacteriophage T4; Nanoparticle vaccine platform; PA; Virus decoration proteins

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIGEN; NANOPARTICLE; BACTERIAL ANTIGEN; BACTERIAL TOXIN;

BACILLUS ANTHRACIS; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENTEROBACTERIA PHAGE T4; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; VIRUS CAPSID; GENETICS; IMMUNIZATION; IMMUNOLOGY; PHYSIOLOGY;

ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BACTERIOPHAGE T4; CAPSID; IMMUNIZATION; NANOPARTICLES;

EID: 85017185729     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6869-5_15     Document Type: Chapter

References (24)

1. Andrew R, Michael JH, Martin PC (eds) (2003) Vaccine protocols, vol 87, 2nd edn. Humana Press Inc., Totowa, NJ
2. Sathaliyawala T et al (2006) Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol 80(15):7688-7698
3. Tao P et al (2013) Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog 9(7):e1003495
4. Tao P, Mahalingam M, Rao VB (2016) Highly effective soluble and bacteriophage T4 nanoparticle plague vaccines against Yersinia pestis. Methods Mol Biol 1403:499-518
5. Shivachandra SB et al (2006) In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large fulllength proteins. Virology 345(1):190-198
6. Tao P et al (2013) In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. Proc Natl Acad Sci U S A 110(15):5846-5851
7. Black LW, Rao VB (2012) Structure, assembly, and DNA packaging of the bacteriophage T4 head. Adv Virus Res 82:119-153
8. Fokine A et al (2004) Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A 101(16):6003-6008
9. Ishii T, Yanagida M (1977) The two dispensable structural proteins (soc and hoc) of the T4 phage capsid; their purification and properties, isolation and characterization of the defective mutants, and their binding with the defective heads in vitro. J Mol Biol 109(4):487-514
10. Qin L, Fokine A, O'Donnell E, Rao VB, Rossmann MG (2010) Structure of the small outer capsid protein, Soc: a clamp for stabilizing capsids of T4-like phages. J Mol Biol 395(4):728-741
11. Li Q, Shivachandra SB, Leppla SH, Rao VB (2006) Bacteriophage T4 capsid: a unique platform for efficient surface assembly of macromolecular complexes. J Mol Biol 363(2): 577-588
12. Li Q, Shivachandra SB, Zhang Z, Rao VB (2007) Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol 370(5):1006-1019
13. Hsu VP et al (2002) Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis 8(10):1039-1043
14. Doolan DL et al (2007) The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 195(2):174-184
15. Moayeri M, Leppla SH, Vrentas C, Pomerantsev AP, Liu S (2015) Anthrax pathogenesis. Annu Rev Microbiol 69:185-208
16. Williamson ED, Dyson EH (2015) Anthrax prophylaxis: recent advances and future directions. Front Microbiol 6:1009
17. Rao M et al (2011) Highly effective generic adjuvant systems for orphan or poverty-related vaccines. Vaccine 29(5):873-877
18. Peachman KK et al (2012) Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores. Clin Vaccine Immunol 19(1):11-16
19. Scorpio A, Blank TE, Day WA, Chabot DJ (2006) Anthrax vaccines: pasteur to the present. Cell Mol Life Sci 63(19-20):2237-2248
20. Kaur M, Singh S, Bhatnagar R (2013) Anthrax vaccines: present status and future prospects. Expert Rev Vaccines 12(8):955-970
21. Grabenstein JD (2008) Vaccines: countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 46(1):129-136
22. Shivachandra SB et al (2007) Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 25(7):1225-1235
23. Bellanti JA et al (2012) Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis. Clin Vaccine Immunol 19(2):140-145
24. Peachman KK et al (2006) Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 74(1):794-797